Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 1NCT05764954
Official study title

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Study summary

The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNovoTTF-200T System

The study team can explain what participation involves.

Who it may be forAdenocarcinoma of Lung

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 28, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Device: NovoTTF-200T System
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
  • The participant is ≥22 years of age on the day of signing informed consent.
  • The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
  • The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
  • The participant with multiple nodules has one nodule that meets the criteria.
  • The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Reasons someone may not be able to joinExclusion criteria
  • Patients receiving therapy for concurrent active malignancy
  • Patients with a history of cardiac arrhythmias and/or pacemaker use
  • Patients with lung nodules \<1cm
  • Patients with lung nodules that are pure ground glass opacities (GGOs) of any size
  • Patients with lung nodules that are \<50% solid of any size

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering Basking Ridge (Consent Only)Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Consent Only)Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk - Commack (Consent Only)Commack, New York
  • Memorial Sloan Kettering Westchester (Consent Only)Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
  • Memorial Sloan Kettering Nassau (Consent Only)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 28, 2026. Always confirm current availability with the study team.

View original record ↗